LIVIVO - Das Suchportal für Lebenswissenschaften

switch to English language
Erweiterte Suche

Ihre letzten Suchen

  1. AU="Kim, Dalsik"
  2. AU="Shiner, Yotam"
  3. AU="Ali, Mir Mohammad"
  4. AU="Weck Melanie"
  5. AU=Martinez-Riera Jose Ramon AU=Martinez-Riera Jose Ramon
  6. AU="Spano, Luana"
  7. AU="Macomb, Christopher V"
  8. AU="Cylwik, Jolanta"
  9. AU="Mirzabeigi, Parastoo"
  10. AU="Lesage, C"
  11. AU=Kim Donghyun AU=Kim Donghyun
  12. AU="Weisburd, Ben"
  13. AU="van den Berg, Linda M"
  14. AU="Kurochkina, Yu D"
  15. AU="H Cao"
  16. AU="Elias, Rui"
  17. AU="Hofstaedter, Ferdinand"
  18. AU="Ross, Ashley E"
  19. AU="Luque Alarcón, Mónica"

Suchergebnis

Treffer 1 - 10 von insgesamt 17

Suchoptionen

  1. Artikel ; Online: Analytical Performance of the Sysmex HISCL HBsAg Assay and Comparison with the Roche Elecsys HBsAg II Quant Assay in the Quantification of Hepatitis B Surface Antigen.

    Park, Joonhong / Bae, Taewon / Cho, Yonggon / Kim, Dalsik / Lee, Jaehyeon

    Medicina (Kaunas, Lithuania)

    2021  Band 57, Heft 12

    Abstract: Background and ... ...

    Abstract Background and Objectives
    Mesh-Begriff(e) Hepatitis B Surface Antigens ; Hepatitis B virus ; Hepatitis B, Chronic ; Humans
    Chemische Substanzen Hepatitis B Surface Antigens
    Sprache Englisch
    Erscheinungsdatum 2021-11-29
    Erscheinungsland Switzerland
    Dokumenttyp Journal Article
    ZDB-ID 2188113-3
    ISSN 1648-9144 ; 1010-660X
    ISSN (online) 1648-9144
    ISSN 1010-660X
    DOI 10.3390/medicina57121307
    Datenquelle MEDical Literature Analysis and Retrieval System OnLINE

    Zusatzmaterialien

    Kategorien

  2. Artikel ; Online: Effect of fermented red ginseng on cytochrome P450 and P-glycoprotein activity in healthy subjects, as evaluated using the cocktail approach.

    Kim, Min-Gul / Kim, Yunjeong / Jeon, Ji-Young / Kim, Dal-Sik

    British journal of clinical pharmacology

    2016  Band 82, Heft 6, Seite(n) 1580–1590

    Abstract: Aims: We assessed the drug interaction profile of fermented red ginseng with respect to the activity of major cytochrome (CYP) P450 enzymes and of a drug transporter protein, P-glycoprotein (P-gp), in healthy volunteers.: Methods: This study was an ... ...

    Abstract Aims: We assessed the drug interaction profile of fermented red ginseng with respect to the activity of major cytochrome (CYP) P450 enzymes and of a drug transporter protein, P-glycoprotein (P-gp), in healthy volunteers.
    Methods: This study was an open-label crossover study. The CYP probe cocktail drugs caffeine, losartan, dextromethorphan, omeprazole, midazolam and fexofenadine were administered before and after 2 weeks of fermented red ginseng administration. Plasma samples were collected, and tolerability was assessed. Pharmacokinetic parameters were calculated, and the 90% confidence intervals (CIs) of the geometric mean ratios of the parameters were determined from logarithmically transformed data. Values were compared between before and after fermented red ginseng administration using analysis of variance (anova).
    Results: Fifteen healthy male subjects were evaluated, none of whom were genetically defined as a poor CYP2C9, CYP2C19 or CYP2D6 metabolizer based on genotyping. Before and after fermented red ginseng administration, the geometric least-square mean metabolic ratio (90% CI) was 0.901 (0.830-0.979) for caffeine (CYP1A2) to paraxanthine, 0.774 (0.720-0.831) for losartan (CYP2C9) to EXP3174, 1.052 (0.925-1.197) for omeprazole (CYP2C19) to 5-hydroxyomeprazole, 1.150 (0.860-1.538) for dextromethorphan (CYP2D6) to dextrorphan, and 0.816 (0.673-0.990) for midazolam (CYP3A4) to 1-hydroxymidazolam. The geometric mean ratio of the area under the curve of the last sampling time (AUC
    Conclusion: No significantly different drug interactions were observed between fermented red ginseng and the CYP probe substrates following the two-week administration of concentrated fermented red ginseng. However, the inhibition of P-gp was significantly different between fermented red ginseng and the CYP probe substrates. The use of fermented red ginseng requires close attention due to the potential for increased systemic exposure when it is used in combination with P-gp substrate drugs.
    Mesh-Begriff(e) ATP Binding Cassette Transporter, Subfamily B, Member 1/metabolism ; Adult ; Caffeine/administration & dosage ; Caffeine/pharmacokinetics ; Cross-Over Studies ; Cytochrome P-450 CYP2C9/metabolism ; Cytochrome P-450 CYP3A/metabolism ; Drug Interactions ; Fermented Foods and Beverages ; Healthy Volunteers ; Humans ; Losartan/administration & dosage ; Losartan/pharmacokinetics ; Male ; Midazolam/administration & dosage ; Midazolam/pharmacokinetics ; Middle Aged ; Omeprazole/administration & dosage ; Omeprazole/pharmacokinetics ; Panax ; Pharmaceutical Preparations/administration & dosage ; Pharmaceutical Preparations/metabolism ; Terfenadine/administration & dosage ; Terfenadine/analogs & derivatives ; Terfenadine/pharmacokinetics ; Young Adult
    Chemische Substanzen ATP Binding Cassette Transporter, Subfamily B, Member 1 ; Pharmaceutical Preparations ; Caffeine (3G6A5W338E) ; Terfenadine (7BA5G9Y06Q) ; fexofenadine (E6582LOH6V) ; CYP2C9 protein, human (EC 1.14.13.-) ; Cytochrome P-450 CYP2C9 (EC 1.14.13.-) ; Cytochrome P-450 CYP3A (EC 1.14.14.1) ; CYP3A4 protein, human (EC 1.14.14.55) ; Losartan (JMS50MPO89) ; Omeprazole (KG60484QX9) ; Midazolam (R60L0SM5BC)
    Sprache Englisch
    Erscheinungsdatum 2016-10-09
    Erscheinungsland England
    Dokumenttyp Journal Article
    ZDB-ID 188974-6
    ISSN 1365-2125 ; 0306-5251 ; 0264-3774
    ISSN (online) 1365-2125
    ISSN 0306-5251 ; 0264-3774
    DOI 10.1111/bcp.13080
    Datenquelle MEDical Literature Analysis and Retrieval System OnLINE

    Zusatzmaterialien

    Kategorien

  3. Artikel: Effect of Red Ginseng on cytochrome P450 and P-glycoprotein activities in healthy volunteers

    Kim, Dal-Sik / Kim, Yunjeong / Jeon, Ji-Young / Kim, Min-Gul

    Journal of Ginseng Research. 2016 Oct., v. 40, no. 4

    2016  

    Abstract: We evaluated the drug interaction profile of Red Ginseng (RG) with respect to the activities of major cytochrome P450 (CYP) enzymes and the drug transporter P-glycoprotein (P-gp) in healthy Korean volunteers.This article describes an open-label, ... ...

    Abstract We evaluated the drug interaction profile of Red Ginseng (RG) with respect to the activities of major cytochrome P450 (CYP) enzymes and the drug transporter P-glycoprotein (P-gp) in healthy Korean volunteers.This article describes an open-label, crossover study. CYP probe cocktail drugs, caffeine, losartan, dextromethorphan, omeprazole, midazolam, and fexofenadine were administered before and after RG supplementation for 2 wk. Plasma samples were collected, and tolerability was assessed. Pharmacokinetic parameters were calculated, and 90% confidence intervals (CIs) of the geometric mean ratios of the parameters were determined from logarithmically transformed data using analysis of variance after RG administration versus before RG administration.Fourteen healthy male participants were evaluated, none of whom were genetically defined as poor CYP2C9, 2C19, and CYP2D6 metabolizers based on genotyping. Before and after RG administration, the geometric least-square mean metabolic ratio (90% CI) was 0.870 (0.805–0.940) for caffeine to paraxanthine (CYP1A2), 0.871 (0.800–0.947) for losartan (CYP2C9) to EXP3174, 1.027 (0.938–1.123) for omeprazole (CYP2C19) to 5-hydroxyomeprazole, 1.373 (0.864–2.180) for dextromethorphan to dextrorphan (CYP2D6), and 0.824 (0.658–1.032) for midazolam (CYP3A4) to 1-hydroxymidazolam. The geometric mean ratio of the area under the curve of the last sampling time (AUCₗₐₛₜ) for fexofenadine (P-gp) was 0.963 (0.845–1.098). Administration of concentrated RG for 2 wk weakly inhibited CYP2C9 and CYP3A4 and weakly induced CYP2D6. However, no clinically significant drug interactions were observed between RG and CYP and P-gp probe substrates.RG has no relevant potential to cause CYP enzyme- or P-gp-related interactions.Clinical trial registration number (ClinicalTrials.gov): NCT02056743.
    Schlagwörter P-glycoproteins ; Panax ; analysis of variance ; caffeine ; cross-over studies ; cytochrome P-450 ; drug interactions ; drugs ; genotyping ; males ; pharmacokinetics ; research
    Sprache Englisch
    Erscheinungsverlauf 2016-10
    Umfang p. 375-381.
    Erscheinungsort Elsevier B.V.
    Dokumenttyp Artikel
    ZDB-ID 2765273-7
    ISSN 2093-4947 ; 1226-8453
    ISSN (online) 2093-4947
    ISSN 1226-8453
    DOI 10.1016/j.jgr.2015.11.005
    Datenquelle NAL Katalog (AGRICOLA)

    Zusatzmaterialien

    Kategorien

  4. Artikel: Effect of Red Ginseng on cytochrome P450 and P-glycoprotein activities in healthy volunteers.

    Kim, Dal-Sik / Kim, Yunjeong / Jeon, Ji-Young / Kim, Min-Gul

    Journal of ginseng research

    2015  Band 40, Heft 4, Seite(n) 375–381

    Abstract: Background: We evaluated the drug interaction profile of Red Ginseng (RG) with respect to the activities of major cytochrome P450 (CYP) enzymes and the drug transporter P-glycoprotein (P-gp) in healthy Korean volunteers.: Methods: This article ... ...

    Abstract Background: We evaluated the drug interaction profile of Red Ginseng (RG) with respect to the activities of major cytochrome P450 (CYP) enzymes and the drug transporter P-glycoprotein (P-gp) in healthy Korean volunteers.
    Methods: This article describes an open-label, crossover study. CYP probe cocktail drugs, caffeine, losartan, dextromethorphan, omeprazole, midazolam, and fexofenadine were administered before and after RG supplementation for 2 wk. Plasma samples were collected, and tolerability was assessed. Pharmacokinetic parameters were calculated, and 90% confidence intervals (CIs) of the geometric mean ratios of the parameters were determined from logarithmically transformed data using analysis of variance after RG administration versus before RG administration.
    Results: Fourteen healthy male participants were evaluated, none of whom were genetically defined as poor CYP2C9, 2C19, and CYP2D6 metabolizers based on genotyping. Before and after RG administration, the geometric least-square mean metabolic ratio (90% CI) was 0.870 (0.805-0.940) for caffeine to paraxanthine (CYP1A2), 0.871 (0.800-0.947) for losartan (CYP2C9) to EXP3174, 1.027 (0.938-1.123) for omeprazole (CYP2C19) to 5-hydroxyomeprazole, 1.373 (0.864-2.180) for dextromethorphan to dextrorphan (CYP2D6), and 0.824 (0.658-1.032) for midazolam (CYP3A4) to 1-hydroxymidazolam. The geometric mean ratio of the area under the curve of the last sampling time (AUC
    Conclusion: RG has no relevant potential to cause CYP enzyme- or P-gp-related interactions. Clinical trial registration number (ClinicalTrials.gov): NCT02056743.
    Sprache Englisch
    Erscheinungsdatum 2015-12-17
    Erscheinungsland Korea (South)
    Dokumenttyp Journal Article
    ZDB-ID 2765273-7
    ISSN 2093-4947 ; 1226-8453
    ISSN (online) 2093-4947
    ISSN 1226-8453
    DOI 10.1016/j.jgr.2015.11.005
    Datenquelle MEDical Literature Analysis and Retrieval System OnLINE

    Zusatzmaterialien

    Kategorien

  5. Artikel: What Do Very Low Plasma Concentrations of High-sensitivity C-reactive Protein (hs-CRP) Mean among Healthy Middle-aged Koreans?

    Kim, Min-Gul / Cho, Baik-Hwan / Chae, Soo-Wan / Park, Tae-Sun / Kim, Dal-Sik

    Journal of lifestyle medicine

    2015  Band 5, Heft 1, Seite(n) 14–20

    Abstract: Background: Systemic low-grade inflammation (SLGI), as assessed by measurements of high-sensitivity C-reactive protein (hs-CRP), is a strong independent risk factor for cardiovascular diseases (CVD). Although individuals with hs-CRP ≤ 1 mg/L have been ... ...

    Abstract Background: Systemic low-grade inflammation (SLGI), as assessed by measurements of high-sensitivity C-reactive protein (hs-CRP), is a strong independent risk factor for cardiovascular diseases (CVD). Although individuals with hs-CRP ≤ 1 mg/L have been defined as being at low risk according to AHA/CDC guidelines, the value of very low hs-CRP levels (<0.5 mg/L) for public health practices is unclear.
    Methods: This cross-sectional cohort study assessed 104 healthy Koreans aged 34-60 years. Their anthropometric indices, results of computed tomography and bioelectrical impedance analysis, and biomarker concentrations in fasting venous blood samples were evaluated.
    Results: Of 104 subjects, 88 (84.6%) had hs-CRP concentrations ≤ 1.0 mg/L. When this low risk group was subdivided into subjects with hs-CRP <0.5 mg/L and hs-CRP levels between 0.5 and 1 mg/L, the former group showed better anthropometric profiles for central obesity and lipidemia.
    Conclusion: Even in low risk subjects, higher serum concentrations of hs-CRP may be associated with increased central obesity. Lifestyle modifications to lower hs-CRP should be recommended in public health practice, with hs-CRP viewed not as a risk marker, but rather as a marker of wellness.
    Sprache Englisch
    Erscheinungsdatum 2015-03-30
    Erscheinungsland Korea (South)
    Dokumenttyp Journal Article
    ZDB-ID 3021714-3
    ISSN 2288-1557 ; 2234-8549
    ISSN (online) 2288-1557
    ISSN 2234-8549
    DOI 10.15280/jlm.2015.5.1.14
    Datenquelle MEDical Literature Analysis and Retrieval System OnLINE

    Zusatzmaterialien

    Kategorien

  6. Artikel ; Online: Reduction of blood lipid parameters by a 12-wk supplementation of aged black garlic: a randomized controlled trial.

    Jung, Eun-Soo / Park, Soo-Hyun / Choi, Eun-Kyung / Ryu, Beun-Ho / Park, Byung-Hyun / Kim, Dal-Sik / Kim, Young-Gon / Chae, Soo-Wan

    Nutrition (Burbank, Los Angeles County, Calif.)

    2014  Band 30, Heft 9, Seite(n) 1034–1039

    Abstract: Objective: The cholesterol-lowering effects of garlic as part of a healthy diet remain controversial. The aim of this study was to investigate whether supplementation with aged black garlic (ABG) could improve blood lipid profiles in patients with mild ... ...

    Abstract Objective: The cholesterol-lowering effects of garlic as part of a healthy diet remain controversial. The aim of this study was to investigate whether supplementation with aged black garlic (ABG) could improve blood lipid profiles in patients with mild hypercholesterolemia.
    Methods: We conducted a double-blind, randomized placebo-controlled trial. Sixty participants were randomly assigned to receive either ABG or placebo twice daily (total 6 g/d) before consumption of a meal every morning and evening for 12 wk. During the study, two participants dropped out of the ABG group, and three participants dropped out of the placebo group. Thus, the effects of AGB on fasting blood levels of lipids were evaluated in 28 participants and compared with the placebo group (n = 27).
    Results: Among lipid components, no significant differences in triglycerides, low-density lipoprotein cholesterol, total cholesterol, or free fatty acid levels were observed between the two groups. However, ABG increased high-density lipoprotein cholesterol levels compared with the placebo group at the end of the study. Moreover, a significant decrease in the levels of alipoprotein B and a significant increase in the ratio of low-density lipoprotein cholesterol/alipoprotein B were observed in the ABG group. No adverse effects were reported in any of the patients.
    Conclusion: ABG supplementation reduced atherogenic markers and thus may have a cardioprotective effect beyond the gold standard medication in patients with mild hypercholesterolemia.
    Mesh-Begriff(e) Adult ; Anticholesteremic Agents/pharmacology ; Anticholesteremic Agents/therapeutic use ; Apolipoproteins B/blood ; Cholesterol, HDL/blood ; Cholesterol, LDL/blood ; Dietary Supplements ; Double-Blind Method ; Female ; Garlic ; Humans ; Hypercholesterolemia/blood ; Hypercholesterolemia/drug therapy ; Lipids/blood ; Male ; Middle Aged ; Plant Preparations/pharmacology ; Plant Preparations/therapeutic use ; Triglycerides/blood
    Chemische Substanzen Anticholesteremic Agents ; Apolipoproteins B ; Cholesterol, HDL ; Cholesterol, LDL ; Lipids ; Plant Preparations ; Triglycerides
    Sprache Englisch
    Erscheinungsdatum 2014-09
    Erscheinungsland United States
    Dokumenttyp Journal Article ; Randomized Controlled Trial ; Research Support, Non-U.S. Gov't
    ZDB-ID 639259-3
    ISSN 1873-1244 ; 0899-9007
    ISSN (online) 1873-1244
    ISSN 0899-9007
    DOI 10.1016/j.nut.2014.02.014
    Datenquelle MEDical Literature Analysis and Retrieval System OnLINE

    Zusatzmaterialien

    Kategorien

  7. Artikel ; Online: Serum folate and low-density lipoprotein particle size.

    Kim, Dal-Sik / Kim, Young-Kon / Park, Hyeong-Kyu / Cho, Young I / Jeong, Seul-Ki

    Journal of atherosclerosis and thrombosis

    2010  Band 17, Heft 12, Seite(n) 1218–1225

    Abstract: Aim: Nutritional parameters, such as B-vitamins, have not been studied for an association with low-density lipoprotein (LDL) particle size. The present study explored whether serum vitamin levels, including folate and vitamin B-12, could be associated ... ...

    Abstract Aim: Nutritional parameters, such as B-vitamins, have not been studied for an association with low-density lipoprotein (LDL) particle size. The present study explored whether serum vitamin levels, including folate and vitamin B-12, could be associated with LDL particle size.
    Methods: Using a randomly selected population of 255 hospital workers, we collected detailed lipid profiles, including triglyceride (TG), high-density lipoprotein (HDL) cholesterol, and LDL particle sizes. The peak particle size of LDL was measured by density gradient ultracentrifugation and a pore gradient lipoprotein system. Serum folate and vitamin B-12 levels were measured about 1 year later and analyzed. Carotid intima-media thickness (IMT) and hepatic steatosis were diagnosed ultrasonographically, and metabolic syndrome was diagnosed using ATP III criteria.
    Results: LDL peak particle size was significantly correlated with carotid mean IMT (r=-0.16, p=0.010). Serum folate levels were significantly and positively correlated with HDL cholesterol and negatively with TG, although the latter showed borderline significance. With increasing serum folate levels, the LDL peak particle size showed a gradual independent increase, even when adjusted for age, sex, hepatic steatosis, metabolic syndrome, and the TG/HDL cholesterol ratio.
    Conclusion: Folate may act to enhance LDL particle size. Future clinical and research work should include a study of the safe application and manipulation of folate levels in order to control LDL particle size.
    Mesh-Begriff(e) Carotid Arteries/diagnostic imaging ; Fatty Liver/diagnostic imaging ; Folic Acid/blood ; Humans ; Lipids/blood ; Lipoproteins, LDL/blood ; Lipoproteins, LDL/ultrastructure ; Particle Size ; Tunica Intima/diagnostic imaging ; Ultrasonography ; Vitamin B Complex
    Chemische Substanzen Lipids ; Lipoproteins, LDL ; Vitamin B Complex (12001-76-2) ; Folic Acid (935E97BOY8)
    Sprache Englisch
    Erscheinungsdatum 2010-08-27
    Erscheinungsland Japan
    Dokumenttyp Journal Article ; Research Support, Non-U.S. Gov't
    ZDB-ID 2011474-6
    ISSN 1880-3873 ; 1340-3478
    ISSN (online) 1880-3873
    ISSN 1340-3478
    DOI 10.5551/jat.5629
    Datenquelle MEDical Literature Analysis and Retrieval System OnLINE

    Zusatzmaterialien

    Kategorien

  8. Artikel: Rosuvastatin Reduces Blood Viscosity in Patients with Acute Coronary Syndrome.

    Jung, Lae-Young / Lee, Sang-Rok / Jung, Jin-Mu / Kim, Yi-Shik / Lee, Sun-Hwa / Rhee, Kyoung-Suk / Chae, Jei-Keon / Lee, Dong-Hwan / Kim, Dal-Sik / Kim, Won-Ho / Ko, Jae-Ki

    Korean circulation journal

    2016  Band 46, Heft 2, Seite(n) 147–153

    Abstract: Background and objectives: Wall shear stress contributes to atherosclerosis progression and plaque rupture. There are limited studies for statin as a major contributing factor on whole blood viscosity (WBV) in patients with acute coronary syndrome (ACS). ...

    Abstract Background and objectives: Wall shear stress contributes to atherosclerosis progression and plaque rupture. There are limited studies for statin as a major contributing factor on whole blood viscosity (WBV) in patients with acute coronary syndrome (ACS). This study investigates the effect of statin on WBV in ACS patients.
    Subjects and methods: We prospectively enrolled 189 consecutive patients (mean age, 61.3±10.9 years; 132 males; ST-segment elevation myocardial infarction, n=52; non-ST-segment elevation myocardial infarction, n=84; unstable angina n=53). Patients were divided into two groups (group I: previous use of statins for at least 3 months, n=51; group II: statin-naïve patients, n=138). Blood viscosities at shear rates of 1 s-1 (diastolic blood viscosity; DBV) and 300 s-1 (systolic blood viscosity; SBV) were measured at baseline and one month after statin treatment. Rosuvastatin was administered to patients after enrollment (mean daily dose, 16.2±4.9 mg).
    Results: Baseline WBV was significantly higher in group II ([SBV: group I vs group II, 40.8±5.9 mP vs. 44.2±7.4 mP, p=0.003], [DBV: 262.2±67.8 mP vs. 296.9±76.0 mP, p=0.002]). WBV in group II was significantly lower one month after statin treatment ([SBV: 42.0±4.7 mP, p=0.012, DBV: 281.4±52.6 mP, p=0.044]). However, low-density lipoprotein cholesterol level was not associated with WBV in both baseline (SBV: R2=0.074, p=0.326; DBV: R2=0.073, p=0.337) and after one month follow up (SBV: R2=0.104, p=0.265; DBV: R2=0.112, p=0.232).
    Conclusion: Previous statin medication is an important determinant in lowering WBV in patients with ACS. However, one month of rosuvastatin decreased WBV in statin-naïve ACS patients.
    Sprache Englisch
    Erscheinungsdatum 2016-03-21
    Erscheinungsland Korea (South)
    Dokumenttyp Journal Article
    ZDB-ID 2557464-4
    ISSN 1738-5520
    ISSN 1738-5520
    DOI 10.4070/kcj.2016.46.2.147
    Datenquelle MEDical Literature Analysis and Retrieval System OnLINE

    Zusatzmaterialien

    Kategorien

  9. Artikel: A double mutation of the ryanodine receptor type 1 gene in a malignant hyperthermia family with multiminicore myopathy.

    Jeong, Seul-Ki / Kim, Dong-Chan / Cho, Yong-Gon / Sunwoo, Il-Nam / Kim, Dal-Sik

    Journal of clinical neurology (Seoul, Korea)

    2008  Band 4, Heft 3, Seite(n) 123–130

    Abstract: Background and purpose: At least 100 Ryanodine receptor type 1 (RYR1) mutations associated with malignant hyperthermia (MH) and central core disease (CCD) have been identified, but 2 RYR1 mutations accompanying multiminicore myopathy in an MH and/or CCD ...

    Abstract Background and purpose: At least 100 Ryanodine receptor type 1 (RYR1) mutations associated with malignant hyperthermia (MH) and central core disease (CCD) have been identified, but 2 RYR1 mutations accompanying multiminicore myopathy in an MH and/or CCD family have been reported only rarely.
    Methods: Fifty-three members of a large MH family were investigated with clinical, histopathologic, RYR1 mutation, and haplotyping studies. Blood creatine kinase (CK) and myoglobin levels were also measured where possible.
    Results: Sequencing of the entire RYR1 coding region identified a double RYR1 mutation (R2435H and A4295V) in MH/CCD regions 2 and 3. Haplotyping analysis revealed that the two missense heterozygous mutations (c.7304G>A and c.12891C>T) were always present on a common haplotype allele, and were closely cosegregated with histological multiminicores and elevated serum CK. All the subjects with the double mutation showed elevated serum CK and myoglobin, and the obtained muscle biopsy samples showed multiminicore lesions, but only two family members presented a late-onset, slowly progressive myopathy.
    Conclusions: We found multiminicore myopathy with clinical and histological variability in a large MH family with an unusual double RYR1 mutation, including a typical CCD-causing known mutant. These results suggest that multiminicore lesions are associated with the presence of more than two mutations in the RYR1 gene.
    Sprache Englisch
    Erscheinungsdatum 2008-09-30
    Erscheinungsland Korea (South)
    Dokumenttyp Journal Article
    ZDB-ID 2500489-X
    ISSN 2005-5013 ; 1738-6586
    ISSN (online) 2005-5013
    ISSN 1738-6586
    DOI 10.3988/jcn.2008.4.3.123
    Datenquelle MEDical Literature Analysis and Retrieval System OnLINE

    Zusatzmaterialien

    Kategorien

  10. Artikel: Impact of visceral fat on the metabolic syndrome and nonalcoholic fatty liver disease.

    Jeong, Seul-Ki / Kim, Young-Kon / Park, Jin-Woo / Shin, Yong-Ju / Kim, Dal-Sik

    Journal of Korean medical science

    2008  Band 23, Heft 5, Seite(n) 789–795

    Abstract: Visceral fat has been reported to be associated with nonalcoholic fatty liver disease (NAFLD) and the metabolic syndrome (MetS). We assessed the prevalence of both NAFLD and the MetS, measured visceral fat thickness VFT), and estimated the physical ... ...

    Abstract Visceral fat has been reported to be associated with nonalcoholic fatty liver disease (NAFLD) and the metabolic syndrome (MetS). We assessed the prevalence of both NAFLD and the MetS, measured visceral fat thickness VFT), and estimated the physical activity indexes of 224 relatively healthy hospital workers. We also investigated the associations between both VFT and physical activity index and each of NAFLD and the MetS. The MetS was diagnosed according to the guidelines outlined by the Adult Treatment Panel III, and NAFLD was diagnosed by ultrasonography. Subjects with hepatitis B and C infections and those reporting moderate alcohol consumption were excluded from the study. The prevalence of the MetS was 11.6% and that of NAFLD was 41.5%. Many subjects with the MetS had NAFLD (73.1%), and some subjects with NAFLD (20.4%) also had several components of the MetS (p=0.001). VFT was significantly increased by both the addition of components of the MetS and the severity of NAFLD (p<0.001). In addition, VFT was independently associated with NAFLD (odds ratio [OR], 1.10; 95% confidence interval [CI], 1.02-1.19) in subjects with more than 2 components of the MetS. In contrast, habitual physical activity was reversely associated with NAFLD (OR, 0.29; 95% CI, 0.10-0.87). In conclusion, an increased visceral fat content and reduced physical activity could be not only biological markers but also therapeutic targets in the treatment of NAFLD and the MetS.
    Mesh-Begriff(e) Adult ; Alcohol Drinking ; Blood Pressure ; Comorbidity ; Fatty Liver/physiopathology ; Female ; Humans ; Hyperinsulinism/complications ; Intra-Abdominal Fat ; Male ; Metabolic Syndrome/physiopathology ; Middle Aged ; Multivariate Analysis ; Odds Ratio
    Sprache Englisch
    Erscheinungsdatum 2008-10
    Erscheinungsland Korea (South)
    Dokumenttyp Journal Article ; Research Support, Non-U.S. Gov't
    ZDB-ID 639262-3
    ISSN 1011-8934
    ISSN 1011-8934
    DOI 10.3346/jkms.2008.23.5.789
    Datenquelle MEDical Literature Analysis and Retrieval System OnLINE

    Zusatzmaterialien

    Kategorien

Zum Seitenanfang